S-14,671
(Preusmjereno sa stranice YFNZHCXOYLKDGU-UHFFFAOYSA-N)
S-14,671 je naftilpiperazinski derivat koji deluje kao agonist 5-HT1A receptora (pKi = 9.3) sa visokom efikasnošću i izuzetnom in vivo potencijom. On je isto tako antagonist 5-HT2A i 5-HT2C receptor (oba imaju pKi = 7.8).[4][5] On pokazuje samo nizak afinitet za 5-HT1B i 5-HT3 receptore.[5]
(IUPAC) ime | |||
---|---|---|---|
N-{2-[4-(7-metoksinaftalen-1-il)piperazin-1-il]etil}tiofen-2-karboksamid | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 135722-27-9 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 131907 | ||
ChemSpider[3] | 116529 | ||
Hemijski podaci | |||
Formula | C22H25N3O2S | ||
Mol. masa | 395,52 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status |
Reference uredi
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Millan MJ, Canton H, Rivet JM, Lejeune F, Laubie M, Lavielle G (October 1991). „S 14671: a novel naphthylpiperazine 5-HT1A agonist of high efficacy and exceptional in vivo potency”. European Journal of Pharmacology 203 (2): 319–22. DOI:10.1016/0014-2999(91)90734-8. PMID 1839284.
- ↑ 5,0 5,1 Millan MJ, Rivet JM, Canton H, et al. (August 1992). „S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors”. The Journal of Pharmacology and Experimental Therapeutics 262 (2): 451–63. PMID 1323650.